Favipiravir

Favipiravir

SCHEMBL21085196

NC(=O)c1nc(F)cnc1O.[NaH]

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PAPB1PB2

The experimentally established mechanism targets of Favipiravir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
LCK P06239 1/20 0.33
KMT2A Q03164 2/20 0.31
MEN1 O00255 1/20 0.31
PDPK1 O15530 1/20 0.31
ADORA3 P0DMS8 1/20 0.31
TSHR P16473 1/20 0.31
MC4R P32245 1/20 0.31
ADRA1A P35348 1/20 0.31
MC3R P41968 1/20 0.31
IKBKB O14920 1/20 0.30
AURKA O14965 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Favipiravir SCHEMBL587913 0.98 LCK (0.34) LCKKMT2AMEN1PDPK1ADORA3
Favipiravir SCHEMBL30725561 0.96 LCK (0.33) LCKKMT2AMEN1PDPK1ADORA3
Favipiravir SCHEMBL28964779 0.85 LMNA (0.32)
SCHEMBL5269681 0.82 PLAU (0.33) LCKKMT2APDPK1ADORA3TSHR
SCHEMBL31259490 0.82 PLAU (0.33) LCKKMT2APDPK1ADORA3TSHR
Favipiravir SCHEMBL28952948 0.81 PARP1 (0.38)
SCHEMBL28398570 0.80 KDM4E (0.37) KMT2AMEN1TSHR
SCHEMBL6376447 0.80 KMT2A (0.32) LCKKMT2AMEN1PDPK1ADORA3
SCHEMBL29733656 0.80 KMT2A (0.32) LCKKMT2AMEN1PDPK1ADORA3
SCHEMBL25028569 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019131223-A1 METHOD FOR PRODUCING FREEZE-DRIED FORMULATION 富士フイルム富山化学株式会社 2019-07-04 WO disclosed